English (United Kingdom)

https://curated-unify.zendy.io/wp-json/zendy-region/v1/featured_content/oa?rat=en

https://curated-unify.zendy.io/wp-json/zendy-region/v1/highlighted_journal/

Zendy Plus

Presents the access of premium content as premium feature

Premium Content

Presents the keyphrase highlighting as premium feature

Keyphrase Highlighting

Presents the summarisation as premium feature

Summarisation

Insights

Presents the pdf analysis as premium feature

PDF Analysis

Presents the zaia usage as premium feature

ZAIA

Zendy Tools

Zendy Open

In recent years, Epstein‐Barr virus ( EBV ) lytic infection has been shown to significantly contribute to carcinogenesis. Thus, therapies aimed at targeting the  EBV  lytic cycle have been developed as novel strategies for treatment of  EBV ‐associated malignancies. In this review, focusing on the viral lytic proteins, we describe recent advances regarding the involvement of the  EBV  lytic cycle in carcinogenesis. Moreover, we further discuss 2 distinct  EBV  lytic cycle‐targeted therapeutic strategies against  EBV ‐induced malignancies. One of the strategies involves inhibition of the  EBV  lytic cycle by natural compounds known to have anti‐ EBV  properties; another is to intentionally induce  EBV  lytic replication in combination with nucleotide analogues. Recent advances in  EBV  lytic‐based strategies are beginning to show promise in the treatment and/or prevention of  EBV ‐related tumors.

Therapies based on targeting Epstein‐Barr virus lytic replication for EBV ‐associated malignancies